Sorcin promotes migration in cancer and regulates the EGF-dependent EGFR signaling pathways.
Calcium
Cancer
EGF
EGFR
Epithelial-to-mesenchymal transition
Invasion
Migration
Signaling
Sorcin
Journal
Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402
Informations de publication
Date de publication:
13 Jul 2023
13 Jul 2023
Historique:
received:
10
11
2022
accepted:
28
06
2023
revised:
03
06
2023
medline:
17
7
2023
pubmed:
14
7
2023
entrez:
13
7
2023
Statut:
epublish
Résumé
The epidermal growth factor receptor (EGFR) is one of the main tumor drivers and is an important therapeutic target for many cancers. Calcium is important in EGFR signaling pathways. Sorcin is one of the most important calcium sensor proteins, overexpressed in many tumors, that promotes cell proliferation, migration, invasion, epithelial-to-mesenchymal transition, malignant progression and resistance to chemotherapeutic drugs. The present work elucidates a functional mechanism that links calcium homeostasis to EGFR signaling in cancer. Sorcin and EGFR expression are significantly correlated and associated with reduced overall survival in cancer patients. Mechanistically, Sorcin directly binds EGFR protein in a calcium-dependent fashion and regulates calcium (dys)homeostasis linked to EGF-dependent EGFR signaling. Moreover, Sorcin controls EGFR proteostasis and signaling and increases its phosphorylation, leading to increased EGF-dependent migration and invasion. Of note, silencing of Sorcin cooperates with EGFR inhibitors in the regulation of migration, highlighting calcium signaling pathway as an exploitable target to enhance the effectiveness of EGFR-targeting therapies.
Identifiants
pubmed: 37442828
doi: 10.1007/s00018-023-04850-4
pii: 10.1007/s00018-023-04850-4
pmc: PMC10345051
doi:
Substances chimiques
Epidermal Growth Factor
62229-50-9
Calcium
SY7Q814VUP
ErbB Receptors
EC 2.7.10.1
EGFR protein, human
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
202Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL167195
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Caldieri G, Barbieri E, Nappo G, Raimondi A, Bonora M, Conte A et al (2017) Reticulon 3-dependent ER-PM contact sites control EGFR nonclathrin endocytosis. Science 356(6338):617–624
pubmed: 28495747
pmcid: 5432029
doi: 10.1126/science.aah6152
da Santos ES, Nogueira KAB, Fernandes LCC, Martins JRP, Reis AVF, de Neto JBV et al (2021) EGFR targeting for cancer therapy: pharmacology and immunoconjugates with drugs and nanoparticles. Int J Pharma 592:120082
doi: 10.1016/j.ijpharm.2020.120082
Avraham R, Yarden Y (2011) Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol 12(2):104–117
pubmed: 21252999
doi: 10.1038/nrm3048
Tomas A, Futter CE, Eden ER (2014) EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol 24(1):26–34
pubmed: 24295852
pmcid: 3884125
doi: 10.1016/j.tcb.2013.11.002
Lindsey S, Langhans SA (2015) Epidermal growth factor signaling in transformed cells. Int Rev Cell Mol Biol 314:1–41
pubmed: 25619714
doi: 10.1016/bs.ircmb.2014.10.001
Pinilla-Macua I, Grassart A, Duvvuri U, Watkins SC, Sorkin A (2017) EGF receptor signaling, phosphorylation, ubiquitylation and endocytosis in tumors in vivo. Elife 6:e31993
pubmed: 29268862
pmcid: 5741375
doi: 10.7554/eLife.31993
Sigismund S, Argenzio E, Tosoni D, Cavallaro E, Polo S, Di Fiore PP (2008) Clathrin-Mediated Internalization Is Essential for Sustained EGFR Signaling but Dispensable for Degradation. Dev Cell 15(2):209–219
pubmed: 18694561
doi: 10.1016/j.devcel.2008.06.012
Goh LK, Sorkin A (2013) Endocytosis of receptor tyrosine kinases. Cold Spring Harb Perspect Biol 5(5):a017459
pubmed: 23637288
pmcid: 3632065
doi: 10.1101/cshperspect.a017459
Thomas R, Weihua Z (2019) Rethink of EGFR in cancer with its kinase independent function on board. Front Oncol 9:800
pubmed: 31508364
pmcid: 6716122
doi: 10.3389/fonc.2019.00800
Uribe ML, Marrocco I, Yarden Y (2021) Egfr in cancer: signaling mechanisms, drugs and acquired resistance. Cancers 13(11):2748
pubmed: 34206026
pmcid: 8197917
doi: 10.3390/cancers13112748
Dokala A, Thakur SS (2017) Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery. Oncogene 36(17):2337–2344
pubmed: 27775071
doi: 10.1038/onc.2016.393
Yamaoka T, Ohba M, Ohmori T (2017) Molecular-targeted therapies for epidermal growth factor receptor and its resistance mechanisms. Int J Mol Sci 18(11):2420
pubmed: 29140271
pmcid: 5713388
doi: 10.3390/ijms18112420
Arteaga CL, Engelman JA (2014) ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 25(3):282–303
pubmed: 24651011
pmcid: 4018830
doi: 10.1016/j.ccr.2014.02.025
Santos RCD, Bautista S, Lucarelli S, Bone LN, Dayam RM, Abousawan J et al (2017) Selective regulation of clathrin-mediated epidermal growth factor receptor signaling and endocytosis by phospholipase C and calcium. Mol Biol Cell 28(21):2802–2818
doi: 10.1091/mbc.e16-12-0871
Martín-Nieto J, Villalobo A (1998) The human epidermal growth factor receptor contains a juxtamembrane calmodulin-binding site. Biochemistry 37(1):227–236
pubmed: 9425043
doi: 10.1021/bi971765v
Li H, Panina S, Kaur A, Ruano MJ, Sánchez-González P, La Cour JM et al (2012) Regulation of the ligand-dependent activation of the epidermal growth factor receptor by calmodulin. J Biol Chem 287(5):3273–3281
pubmed: 22157759
doi: 10.1074/jbc.M111.317529
Abdelli F, Jellali K, Anguita E, González-Muñoz M, Villalobo E, Madroñal I et al (2021) The role of the calmodulin-binding and calmodulin-like domains of the epidermal growth factor receptor in tyrosine kinase activation. J Cell Physiol 236(7):4997–5011
pubmed: 33305427
doi: 10.1002/jcp.30205
Modica TME, Dituri F, Mancarella S, Pisano C, Fabregat I, Giannelli G (2019) Calcium regulates HCC proliferation as well as EGFR recycling/degradation and could be a new therapeutic target in HCC. Cancers (Basel) 11(10):1588
pubmed: 31635301
doi: 10.3390/cancers11101588
Battista T, Fiorillo A, Chiarini V, Genovese I, Ilari A, Colotti G (2020) Roles of sorcin in drug resistance in cancer: One protein, many mechanisms, for a novel potential anticancer drug target. Cancers (Basel). 12(4):887
pubmed: 32268494
pmcid: 7226229
doi: 10.3390/cancers12040887
Genovese I, Ilari A, Assaraf YG, Fazi F, Colotti G (2017) Not only P-glycoprotein: amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. Drug Resist Update 32:46
doi: 10.1016/j.drup.2017.10.003
Zhang J, Guan W, Xu X, Wang F, Li X, Xu G (2021) A novel homeostatic loop of sorcin drives paclitaxel-resistance and malignant progression via Smad4/ZEB1/miR-142-5p in human ovarian cancer. Oncogene 40(30):4906–4918
pubmed: 34163033
pmcid: 8321900
doi: 10.1038/s41388-021-01891-6
Lalioti VS, Ilari A, O’Connell DJ, Poser E, Sandoval IV, Colotti G (2014) Sorcin links calcium signaling to vesicle trafficking, regulates polo-like kinase 1 and is necessary for mitosis. PLoS ONE 9(1):e85438
pubmed: 24427308
pmcid: 3888430
doi: 10.1371/journal.pone.0085438
Zamparelli C, Ilari A, Verzili D, Giangiacomo L, Colotti G, Pascarella S et al (2000) Structure-function relationships in sorcin, a member of the penta EF- hand family. Interaction of sorcin fragments with the ryanodine receptor and an Escherichia coli model system. Biochemistry 39(4):658–666
pubmed: 10651630
doi: 10.1021/bi991648v
Mella M, Colotti G, Zamparelli C, Verzili D, Ilari A, Chiancone E (2003) Information transfer in the penta-EF-hand protein sorcin does not operate via the canonical structural/functional pairing: A study with site-specific mutants. J Biol Chem 278(27):24921–24928
doi: 10.1074/jbc.M213276200
Franceschini S, Ilari A, Verzili D, Zamparelli C, Antaramian A, Rueda A et al (2008) Molecular basis for the impaired function of the natural F112L sorcin mutant: X-ray crystal structure, calcium affinity, and interaction with annexin VII and the ryanodine receptor. FASEB J 22(1):295–306
pubmed: 17699613
doi: 10.1096/fj.07-8988com
Genovese I, Giamogante F, Barazzuol L, Battista T, Fiorillo A, Vicario M et al (2020) Sorcin is an early marker of neurodegeneration, Ca2+ dysregulation and endoplasmic reticulum stress associated to neurodegenerative diseases. Cell Death Dis 11(10):861
pubmed: 33060591
pmcid: 7566454
doi: 10.1038/s41419-020-03063-y
Colotti G, Zamparelli C, Verzili D, Mella M, Loughrey CM, Smith GL et al (2006) The W105G and W99G sorcin mutants demonstrate the role of the D helix in the Ca
pubmed: 17029407
doi: 10.1021/bi060416a
Matsumoto T, Hisamatsu Y, Ohkusa T, Inoue N, Sato T, Suzuki S et al (2005) Sorcin interacts with sarcoplasmic reticulum Ca2+-ATPase and modulates excitation-contraction coupling in the heart. Basic Res Cardiol 100(3):250–262
pubmed: 15754088
doi: 10.1007/s00395-005-0518-7
Fowler MR, Colotti G, Chiancone E, Smith GL, Fearon IM (2008) Sorcin modulates cardiac L-type Ca2+ current by functional interaction with the alpha1C subunit in rabbits. Exp Physiol 93(12):1233–1238
pubmed: 18603601
doi: 10.1113/expphysiol.2008.043497
Fowler MR, Colotti G, Chiancone E, Higuchi Y, Seidler T, Smith GL (2009) Complex modulation of L-type Ca
doi: 10.1007/s00424-008-0575-5
Zamparelli C, Macquaide N, Colotti G, Verzili D, Seidler T, Smith GL et al (2010) Activation of the cardiac Na
pubmed: 20298697
pmcid: 2958309
doi: 10.1016/j.yjmcc.2010.03.003
Berrocal M, Saez L, Mata AM (2021) Sorcin activates the brain PMCA and blocks the inhibitory effects of molecular markers of Alzheimer’s disease on the pump activity. Int J Mol Sci 22(11):6055
pubmed: 34205207
pmcid: 8200006
doi: 10.3390/ijms22116055
Liu X, Chen L, Feng B, Liu G (2014) Reversing effect of sorcin in the drug resistance of human nasopharyngeal carcinoma. Anat Rec 297(2):215–221
doi: 10.1002/ar.22832
Vineeth Daniel P, Dogra S, Rawat P, Choubey A, Khan AS, Rajak S et al (2021) NF-κB p65 regulates hepatic lipogenesis by promoting nuclear entry of ChREBP in response to a high carbohydrate diet. J Biol Chem 296:100714
pubmed: 33930463
pmcid: 8144664
doi: 10.1016/j.jbc.2021.100714
Tuo H, Shu F, She S, Yang M, Zou XQ, Huang J et al (2017) Sorcin induces gastric cancer cell migration and invasion contributing to STAT3 activation. Oncotarget 8(61):104258–104271
pubmed: 29262638
pmcid: 5732804
doi: 10.18632/oncotarget.22208
Li X, Liu Y, Wang Y, Liu J, Li X, Cao H et al (2017) Negative regulation of hepatic inflammation by the soluble resistance-related calcium-binding protein via signal transducer and activator of transcription 3. Front Immunol 8:709
pubmed: 28706517
pmcid: 5489593
doi: 10.3389/fimmu.2017.00709
Gupta K, Sirohi VK, Kumari S, Shukla V, Manohar M, Popli P et al (2018) Sorcin is involved during embryo implantation via activating VEGF/PI3K/Akt pathway in mice. J Mol Endocrinol 60(2):119–132
pubmed: 29273681
doi: 10.1530/JME-17-0153
He Q, Zhang G, Hou D, Leng A, Xu M, Peng J et al (2011) Overexpression of sorcin results in multidrug resistance in gastric cancer cells with up-regulation of P-gp. Oncol Rep 25(1):237–243
pubmed: 21109982
Gong Z, Sun P, Chu H, Zhu H, Sun D, Chen J (2014) Overexpression of sorcin in multidrug-resistant human breast cancer. Oncol Lett 8(6):2393–2398
pubmed: 25364401
pmcid: 4214497
doi: 10.3892/ol.2014.2543
Suarez J, McDonough PM, Scott BT, Suarez-Ramirez A, Wang H, Fricovsky ES et al (2013) Sorcin modulates mitochondrial Ca2+ handling and reduces apoptosis in neonatal rat cardiac myocytes. Am J Physiol Cell Physiol 304(3):C248–C256
pubmed: 23151801
doi: 10.1152/ajpcell.00039.2012
Van der Bliek AM, Baas F, Van der Velde-Koerts T, Biedler JL, Meyers MB, Ozols RF et al (1988) Genes amplified and overexpressed in human multidrug-resistant cell lines. Cancer Res 48(21):5927–5932
pubmed: 2901906
Padar S, Van Breemen C, Thomas DW, Uchizono JA, Livesey JC, Rahimian R (2004) Differential regulation of calcium homeostasis in adenocarcinoma cell line A549 and its Taxol-resistant subclone. Br J Pharmacol 142(2):305–316
pubmed: 15066902
pmcid: 1574945
doi: 10.1038/sj.bjp.0705755
Qi J, Liu N, Zhou Y, Tan Y, Cheng Y, Yang C et al (2006) Overexpression of sorcin in multidrug resistant human leukemia cells and its role in regulating cell apoptosis. Biochem Biophys Res Commun 349(1):303–309
pubmed: 16934756
doi: 10.1016/j.bbrc.2006.08.042
Deng L, Su T, Leng A, Zhang X, Xu M, Yan L et al (2010) Upregulation of soluble resistance-related calcium-binding protein (sorcin) in gastric cancer. Med Oncol 27(4):1102–1108
pubmed: 19885748
doi: 10.1007/s12032-009-9342-5
Maddalena F, Laudiero G, Piscazzi A, Secondo A, Scorziello A, Lombardi V et al (2011) Sorcin induces a drug-resistant phenotype in human colorectal cancer by modulating Ca 2+ homeostasis. Cancer Res 71(24):7659–7669
pubmed: 22052463
doi: 10.1158/0008-5472.CAN-11-2172
Gao Y, Li W, Liu X, Gao F, Zhao X (2015) Reversing effect and mechanism of soluble resistance-related calcium-binding protein on multidrug resistance in human lung cancer A549/DDP cells. Mol Med Rep 11(3):2118–2124
pubmed: 25394367
doi: 10.3892/mmr.2014.2936
Qu Y, Yang Y, Liu B, Xiao W (2010) Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer. Med Oncol 27(4):1303–1308
pubmed: 20012234
doi: 10.1007/s12032-009-9379-5
Tan Y, Li G, Zhao C, Wang J, Zhao H, Xue Y et al (2003) Expression of sorcin predicts poor outcome in acute myeloid leukemia. Leuk Res 27(2):125–131
pubmed: 12526918
doi: 10.1016/S0145-2126(02)00083-8
Zhou Y, Xu Y, Tan Y, Qi J, Xiao Y, Yang C et al (2006) Sorcin, an important gene associated with multidrug-resistance in human leukemia cells. Leuk Res 30(4):469–476
pubmed: 16213583
doi: 10.1016/j.leukres.2005.08.024
Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME et al (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415(6870):436–442
pubmed: 11807556
doi: 10.1038/415436a
Yokota T, Kouno J, Adachi K, Takahashi H, Teramoto A, Matsumoto K et al (2006) Identification of histological markers for malignant glioma by genome-wide expression analysis: dynein, α-PIX and sorcin. Acta Neuropathol 111(1):29–38
pubmed: 16320026
doi: 10.1007/s00401-005-1085-6
Dabaghi M, Rahgozar S, Moshtaghian J, Moafi A, Abedi M, Pourabutaleb E (2016) Overexpression of SORCIN is a prognostic biomarker for multidrug-resistant pediatric acute lymphoblastic leukemia and correlates with upregulated MDR1/P-gp. Genet Test Mol Biomarkers 20(9):516–521
pubmed: 27382961
doi: 10.1089/gtmb.2016.0031
Hu Y, Li S, Yang M, Yan C, Fan D, Zhou Y et al (2014) Sorcin silencing inhibits epithelial-to-mesenchymal transition and suppresses breast cancer metastasis in vivo. Breast Cancer Res Treat 143(2):287–299
pubmed: 24337682
doi: 10.1007/s10549-013-2809-2
Parekh HK, Deng HB, Choudhary K, Houser SR, Simpkins H (2002) Overexpression of sorcin, a calcium-binding protein, induces a low level of paclitaxel resistance in human ovarian and breast cancer cells. Biochem Pharmacol 63(6):1149–1158
pubmed: 11931848
doi: 10.1016/S0006-2952(02)00850-X
Chen X, Weber C, Farrell ET, Alvarado FJ, Zhao YT, Gómez AM, Valdivia HH (2018) Sorcin ablation plus β-adrenergic stimulation generate an arrhythmogenic substrate in mouse ventricular myocytes. J Mol Cell Cardiol 114:199–210
pubmed: 29174767
doi: 10.1016/j.yjmcc.2017.11.017
Genovese I, Fiorillo A, Ilari A, Masciarelli S, Fazi F, Colotti G (2017) Binding of doxorubicin to Sorcin impairs cell death and increases drug resistance in cancer cells. Cell Death Dis 8(7):e2950
pubmed: 28726784
pmcid: 5550883
doi: 10.1038/cddis.2017.342
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium (2020) Pan-cancer analysis of whole genomes. Nature 578:82–93
doi: 10.1038/s41586-020-1969-6
Imamura F, Horai T, Mukai M, Shinkai K, Akedo H (1991) Serum requirement for in vitro invasion by tumor cells. Jpn J Cancer Res 82(5):493–496
pubmed: 1905695
pmcid: 5918475
doi: 10.1111/j.1349-7006.1991.tb01877.x
Chao Y, Wu Q, Acquafondata M et al (2012) Partial mesenchymal to epithelial reverting transition in breast and prostate cancer metastases. Cancer Microenviron 5:19–28
pubmed: 21892699
doi: 10.1007/s12307-011-0085-4
Saxena K, Jolly MK, Balamurugan K (2020) Hypoxia, partial EMT and collective migration: emerging culprits in metastasis. Transl Oncol 13(11):100845
pubmed: 32781367
pmcid: 7419667
doi: 10.1016/j.tranon.2020.100845
Hazan RB, Qiao R, Keren R, Badano I, Suyama K (2004) Cadherin switch in tumor progression. Ann N Y Acad Sci 1014:155–163
pubmed: 15153430
doi: 10.1196/annals.1294.016
Oksvold MP, Pedersen NM, Forfang L, Smeland EB (2012) Effect of cycloheximide on epidermal growth factor receptor trafficking and signaling. FEBS Lett 586(20):3575–3581
pubmed: 22971756
doi: 10.1016/j.febslet.2012.08.022
Ilari A, Fiorillo A, Poser E, Lalioti VS, Sundell GN, Ivarsson Y et al (2015) Structural basis of Sorcin-mediated calcium-dependent signal transduction. Sci Rep 5:16828
pubmed: 26577048
pmcid: 4649501
doi: 10.1038/srep16828
Chang CP, Kao JPY, Lazar CS, Walsh BJ, Wells A, Wiley HS et al (1991) Ligand-induced internalization and increased cell calcium are mediated via distinct structural elements in the carboxyl terminus of the epidermal growth factor receptor. J Biol Chem 266(34):23467–23470
pubmed: 1744139
doi: 10.1016/S0021-9258(18)54520-8
Sharma A, Elble RC (2020) From orai to E-Cadherin: subversion of calcium trafficking in cancer to drive proliferation, anoikis-resistance, and metastasis. Biomedicines 8(6):169
pubmed: 32575848
pmcid: 7345168
doi: 10.3390/biomedicines8060169
Tong W, Sun D, Wang Q, Suo J (2015) Sorcin enhances metastasis and promotes epithelial-to-mesenchymal transition of colorectal cancer. Cell Biochem Biophys 72(2):453–459
pubmed: 25567655
doi: 10.1007/s12013-014-0486-3
Ling F, Zhang H, Sun Y, Meng J, Sanches JGP, Huang H et al (2021) AnnexinA7 promotes epithelial–mesenchymal transition by interacting with Sorcin and contributes to aggressiveness in hepatocellular carcinoma. Cell Death Dis 12(11):1018
pubmed: 34716295
pmcid: 8556303
doi: 10.1038/s41419-021-04287-2
Shah C, Royle B (2019) The NAE pathway: autobahn to the nucleus for cell surface receptors. Cells 8(8):915
pubmed: 31426451
pmcid: 6721735
doi: 10.3390/cells8080915
Xu P, Jiang YF, Wang JH (2015) shRNA-mediated silencing of sorcin increases drug chemosensitivity in myeloma KM3/DDP and U266/ADM cell lines. Int J Clin Exp Pathol 8(3):2300–2310
pubmed: 26045737
pmcid: 4440046
Sun Y, Liu W, Wang C, Meng Q, Liu Z, Huo X et al (2019) Combination of dihydromyricetin and ondansetron strengthens antiproliferative efficiency of adriamycin in K562/ADR through downregulation of SORCIN: a new strategy of inhibiting P-glycoprotein. J Cell Physiol 234(4):3685–3696
pubmed: 30171603
doi: 10.1002/jcp.27141
Meyers MB, Pickel VM, Sheu SS, Sharma VK, Scotto KW, Fishman GI (1995) Association of sorcin with the cardiac ryanodine receptor. J Biol Chem 270:26411–26418
pubmed: 7592856
doi: 10.1074/jbc.270.44.26411
Farrell EF, Antaramian A, Rueda A, Gómez AM, Valdivia HH (2003) Sorcin inhibits calcium release and modulates excitation-contraction coupling in the heart. J Biol Chem 278(36):34660–34666
pubmed: 12824171
doi: 10.1074/jbc.M305931200
Lokuta AJ, Meyers MB, Sander PR, Fishman GI, Valdivia HH (1997) Modulation of cardiac ryanodine receptors by Sorcin. J Biol Chem 272(40):25333–25338
pubmed: 9312152
doi: 10.1074/jbc.272.40.25333
Landriscina M, Laudiero G, Maddalena F, Amoroso MR, Piscazzi A, Cozzolino F et al (2010) Mitochondrial chaperone Trap1 and the calcium binding protein sorcin interact and protect cells against apoptosis induced by antiblastic agents. Cancer Res 70(16):6577–6586
pubmed: 20647321
doi: 10.1158/0008-5472.CAN-10-1256
Marmugi A, Parnis J, Chen X, Carmichael L, Hardy J, Mannan N et al (2016) Sorcin links pancreatic β-cell lipotoxicity to ER Ca2+ stores. Diabetes 65(4):1009–1021
pubmed: 26822088
pmcid: 4806657
doi: 10.2337/db15-1334
Wang D, Shi S, Hsieh YL, Wang J, Wang H, Wang W (2021) Knockdown of sorcin increases HEI-OC1 cell damage induced by cisplatin in vitro. Arch Biochem Biophys 701:108752
pubmed: 33675811
doi: 10.1016/j.abb.2021.108752
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249
pubmed: 33538338
doi: 10.3322/caac.21660
Tang J, Salama R, Gadgeel SM, Sarkar FH, Ahmad A (2013) Erlotinib resistance in lung cancer: current progress and future perspectives. Front Pharmacol 4:15
pubmed: 23407898
pmcid: 3570789
doi: 10.3389/fphar.2013.00015
Faber AC, Li D, Song YC, Liang MC, Yeap BY, Bronson RT et al (2009) Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci USA 106(46):19503–19508
pubmed: 19850869
pmcid: 2765921
doi: 10.1073/pnas.0905056106
Jänne PA, Cohen RB, Laird AD, Macé S, Engelman JA, Ruiz-Soto R, Rockich K, Xu J, Shapiro GI, Martinez P, Felip E (2014) Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors. J Thorac Oncol 9(3):316–323
pubmed: 24496004
doi: 10.1097/JTO.0000000000000088